{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mi-secondary-prevention/prescribing-information/ace-inhibitors/","result":{"pageContext":{"chapter":{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors","depth":2,"htmlHeader":"<!-- begin field 34df409f-19a9-4150-8a7b-a78300ed9847 --><h2>ACE inhibitors</h2><!-- end field 34df409f-19a9-4150-8a7b-a78300ed9847 -->","summary":"","htmlStringContent":"<!-- begin item d03b9363-5e83-4a03-878d-a78300ed95b1 --><!-- end item d03b9363-5e83-4a03-878d-a78300ed95b1 -->","topic":{"id":"10808f6c-5a83-5526-84e2-5998dee92475","topicId":"0b3a22ee-885a-43aa-8d4b-a290dc2afbcc","topicName":"MI - secondary prevention","slug":"mi-secondary-prevention","lastRevised":"Last revised in May 2020","chapters":[{"id":"6d17bc7f-3ed1-5a79-b4f4-8e9dc752c658","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a57b961c-8bba-5c02-8844-b6307b89222c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"dc552ddd-7106-5f5f-a7d9-4b2d6f80e1fa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"e9a32a50-5bdc-5fc0-8ecb-152881ffa7ad","slug":"changes","fullItemName":"Changes"},{"id":"d4c6dcc6-12c6-52a1-957d-47a931a225ec","slug":"update","fullItemName":"Update"}]},{"id":"8c06d36f-1d73-5741-981b-5ed3cc16b7c2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cd13560d-8bec-5902-9a9e-2ce26eaa9028","slug":"goals","fullItemName":"Goals"},{"id":"b9d35945-0a30-523a-9ded-6a2ea7f5a79a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5c84a4ff-a034-50b3-b1a3-7cfecfb1e65c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"02b0b701-c0f0-542f-b958-8d30a81301fc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f516bbb5-ea19-5f8f-be12-d8f550493156","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"cf211bbf-df50-54c9-b204-ef227db8c62f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3ddc8181-0420-5ae4-8326-2d5ef700203a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f303e07d-da7d-5073-b00b-f3dd008f2594","slug":"definition","fullItemName":"Definition"},{"id":"45810734-c13c-5bbd-b314-88dcbfd54c57","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5488a58d-1964-5d60-a54e-a420fd0daeff","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b05c9d6f-fae2-5624-bc64-e5456fa46e84","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"2dd1d8e3-398b-5765-b249-43150874e311","fullItemName":"Management","slug":"management","subChapters":[{"id":"6854ca49-f0af-50f1-8fd3-a6bb900b4bc4","slug":"secondary-prevention","fullItemName":"Scenario: Secondary prevention"}]},{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e43e8d70-7611-5939-94cb-7cc18a3950a6","slug":"ace-inhibitors","fullItemName":"ACE inhibitors"},{"id":"0220c0cb-0802-5bfa-9d8b-f767f73dbea1","slug":"antiplatelet-treatments","fullItemName":"Antiplatelet treatments"},{"id":"a6c13387-db91-5f87-9795-c95a1be0a245","slug":"beta-blockers","fullItemName":"Beta blockers"},{"id":"064bc21b-4d02-5987-9c23-08b1ca8870d1","slug":"statins","fullItemName":"Statins"}]},{"id":"05c20737-02bb-500e-b3e6-0a506d19e727","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1ae6e3bc-f751-5c4b-a14d-09c72b74424e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a3e487f8-13d0-532b-b16f-d448106af2ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"03c8dfe8-3b8b-5c16-ab71-21f98aa13dcd","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a1919ef1-18db-59ab-8c6d-7ef4d649f5d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3e57d884-d476-55de-a85c-a5e4e2001343","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e8c5059d-6ccf-58a3-bb80-1a8273c64c14","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bcfd412e-e461-5a99-a38f-a03a01873fa5","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a4fb09c9-df2a-5800-954a-58fe23af6127","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d50c5710-6df4-5fa7-928b-b28f93e151a5","slug":"general-information","fullItemName":"General information","depth":3,"htmlHeader":"<!-- begin field 5f06cdba-0ed9-421e-9602-aa1400f42baa --><h3>General information</h3><!-- end field 5f06cdba-0ed9-421e-9602-aa1400f42baa -->","summary":"","htmlStringContent":"<!-- begin item 53a73485-2bc8-43b6-a2ed-aa1400f42b2b --><!-- begin field 177f0b91-0e34-44fe-9031-aa1400f42baa --><ul><li><strong>ACE inhibitors:</strong><ul><li>The dose should have been titrated upwards at short intervals (for example, every 12–24 hours) before the person left hospital, until the maximum tolerated or target dose was reached. If it was not possible to complete the titration during this time, it should be completed within 4–6 weeks of hospital discharge — details of current and target dose should have been provided by the initial prescriber.</li><li>For people unable to take ACE inhibitors, an angiotensin-II receptor blocker (ARB) may have been prescribed as an alternative.</li><li>Renal function, serum electrolytes, and blood pressure should have been measured before starting an ACE inhibitor or ARB. These measurements should be repeated within 1 or 2 weeks of starting treatment, and then as appropriate as the dose is titrated upwards, and then at least annually. Details of required monitoring should have been provided by the specialist who initiated treatment.</li><li>An ACE inhibitor is normally continued indefinitely post-MI.</li><li>It may be appropriate to offer an ACE inhibitor to anyone who has had an MI more than 12 months ago and who is not currently taking one.</li><li>For further detailed information on prescribing an ACE inhibitor, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li><li>Patient information leaflets on use of ACE inhibitors in pregnancy are freely available from the UK Teratology Information Service at <a data-hyperlink-id=\"c60a1395-b64f-414c-85b1-aa14015e5d30\" href=\"http://www.medicinesinpregnancy.org/\">www.medicinesinpregnancy.org</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">NICE, 2013</a>]</p><!-- end field 177f0b91-0e34-44fe-9031-aa1400f42baa --><!-- end item 53a73485-2bc8-43b6-a2ed-aa1400f42b2b -->","subChapters":[]},{"id":"28e30e67-d3e0-588f-8e58-c9f5f0ea5dc7","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 67d530c0-4e23-4770-9dae-aa1400f4408a --><h3>Contraindications and cautions</h3><!-- end field 67d530c0-4e23-4770-9dae-aa1400f4408a -->","summary":"","htmlStringContent":"<!-- begin item 0be3ef34-ef6c-412a-a1fa-aa1400f4404d --><!-- begin field e7c92f41-ea11-48db-851e-aa1400f4408a --><ul><li><strong>Use of angiotensin-converting enzyme (ACE) inhibitors is contraindicated in:</strong><ul><li>People with history of angioedema associated with previous exposure to an ACE inhibitor.</li><li>People with hereditary or recurrent angioedema.</li><li>People with diabetes mellitus, or with an eGFR <60 mL/minute/1.73m<sup>2</sup>, who are also taking aliskiren.</li><li>Pregnant women and those planning a pregnancy — due to risks to the fetus. Treatment with an ACE inhibitor should ideally be stopped as soon as pregnancy is detected and, if appropriate, alternative treatment should be started.<ul><li>For more information, see the CKS topics on <a data-hyperlink-id=\"6afefa45-df0a-46d9-8023-aa140126842c\" href=\"https://cks.nice.org.uk/pre-conception-advice-and-management\">Pre-conception - advice and management</a> and <a data-hyperlink-id=\"8e942cbe-3dfd-4745-becc-aa140126844d\" href=\"https://cks.nice.org.uk/hypertension-in-pregnancy\">Hypertension in pregnancy</a>.</li></ul></li><li>Breastfeeding women — ACE inhibitors are not recommended as there is limited information on their safety.</li></ul></li><li><strong>ACE inhibitors should be used with caution in people:</strong><ul><li>Of black African or Caribbean origin, or with primary aldosteronism — may respond less well to ACE inhibitors.</li><li>With renal impairment — hyperkalaemia and other adverse effects are more common, and the dose may need to be reduced. </li><li>Taking diuretics.</li><li>With peripheral vascular disease or generalised artherosclerosis — due to risk of clinically silent renovascular disease.</li><li>With hypertrophic cardiomyopathy.</li><li>With severe or symptomatic aortic stenosis — due to risk of hypotension.</li><li>With collagen vascular disease — possible increased risk of agranulocytosis — blood counts recommended.</li></ul></li><li><strong>Note: </strong>people taking high doses of diuretics, on a low sodium diet, on dialysis, who are dehydrated, or who have heart failure, may be more likely to experience first dose hypotension.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BNF 76, 2018</a>]</p><!-- end field e7c92f41-ea11-48db-851e-aa1400f4408a --><!-- end item 0be3ef34-ef6c-412a-a1fa-aa1400f4404d -->","subChapters":[]},{"id":"c1c133bc-4e8c-5723-bdda-74b080b68971","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e1475567-b33f-4b09-ad7c-aa1400f44e31 --><h3>Adverse effects</h3><!-- end field e1475567-b33f-4b09-ad7c-aa1400f44e31 -->","summary":"","htmlStringContent":"<!-- begin item 5b7ad908-2a0e-4b50-98eb-aa1400f44dc8 --><!-- begin field aaac336e-f05d-4101-b3cf-aa1400f44e31 --><p><strong>Adverse effects of angiotensin-converting enzyme (ACE) inhibitors include:</strong></p><ul><li><strong>Renal impairment </strong>— monitor renal function 1–2 weeks after starting an angiotensin-converting enzyme (ACE) inhibitor, after each increase in dose, and regularly throughout treatment.</li><li><strong>Hyperkalaemia </strong>— monitor<strong> </strong>serum electrolytes 1–2 weeks after starting an ACE inhibitor, after each increase in dose, and regularly throughout treatment.</li><li><strong>Cough</strong> <ul><li>Cough occurs in about 15% of people taking an ACE inhibitor and may occur at any time after starting treatment — if the cough is troublesome (for example, it prevents the person from sleeping) and other causes have been ruled out, consider switching to an angiotensin-II receptor antagonist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">National Clinical Guideline Centre, 2011</a>].</li></ul></li><li><strong>Angioedema</strong><ul><li>ACE inhibitors can cause a non-allergic drug reaction which can precipitate angioedema — stop ACE inhibitor treatment immediately, and consider starting an alternative drug treatment. If possible avoid angiotensin-II receptor antagonists as these can also trigger episodes of angio-oedema. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li><li><strong>Dizziness and headaches </strong><ul><li>Dizziness and headaches occur most commonly in people who are hypovolaemic or hyponatraemic — if hypotension is symptomatic, consider reducing the dose of the ACE inhibitor or stopping it.</li></ul></li><li><strong>Other common adverse effects</strong> include abdominal discomfort, dyspepsia, diarrhoea, nausea and vomiting, rash (in particular maculo-papular rash), myalgia, muscle spasms, dyspnoea, chest pain, and fatigue.</li><li><strong>Hepato-biliary disorders</strong> — stop treatment if marked elevation of hepatic enzymes or jaundice occur. This is a very rare adverse effect. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BNF 76, 2018</a>]</p><!-- end field aaac336e-f05d-4101-b3cf-aa1400f44e31 --><!-- end item 5b7ad908-2a0e-4b50-98eb-aa1400f44dc8 -->","subChapters":[]},{"id":"8d0b61b1-4489-58f9-a3a7-98f67cb39598","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 06300f5b-ebad-4d0c-b017-aa1400f45ac9 --><h3>Drug interactions</h3><!-- end field 06300f5b-ebad-4d0c-b017-aa1400f45ac9 -->","summary":"","htmlStringContent":"<!-- begin item 60dbbb38-8b81-4c50-a48b-aa1400f45a8f --><!-- begin field 707657e7-da99-4ed1-8610-aa1400f45ac9 --><p><strong>Drug interactions with angiotensin-converting enzyme (ACE) inhibitors include:</strong></p><ul><li><strong>Angiotensin-II receptor antagonists and aliskerin</strong> — concomitant use of two drugs affecting the renin-angiotensin system increases the risk of hyperkalaemia, hypotension, and renal impairment.<ul><li>People with diabetic neuropathy are particularly susceptible to developing hyperkalaemia and should not receive combination treatment.</li><li>For people for whom combination therapy is considered essential, specialist supervision with close monitoring of blood pressure, renal function, and electrolytes, is recommended - monitoring should be carried out when treatment commences, then monthly, and also after any change in dose or intercurrent illness.</li></ul></li><li><strong>Diuretics</strong> — ACE inhibitors can cause a very rapid fall in blood pressure in a person who is volume-depleted.<ul><li>Treatment should be initiated at very low doses.</li><li>If the dose of diuretic is greater than 80 mg furosemide or equivalent, the ACE inhibitor should be initiated under close supervision and in some cases the diuretic dose may need to be reduced, or the diuretic discontinued at least 24 hours beforehand.</li><li>If high dose diuretic therapy cannot be stopped, close observation is recommended for at least 2 hours following the first dose of ACE inhibitor, or until the blood pressure has stablised.</li></ul></li><li><strong>Allopurinol</strong> — possible increased risk of leucopenia and hypersensitivity reactions, especially in people with renal impairment.</li><li><strong>Bee/wasp venom extracts</strong> — risk of severe anaphylaxis.</li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — increased risk of renal impairment, and hypotensive effect antagonised with concomitant use.</li><li><strong>Antacids</strong> — possible decreased absorption of ACE inhibitors with use of an antacid.</li><li><strong>Amiloride, eplerenone, heparins, ciclosporin, potassium canrenoate, potassium salts, triamterene, trimethoprim </strong>—  increased risk of hyperkalaemia. Monitoring of electrolytes and renal function may be advised.</li><li><strong>Digoxin</strong> — concomitant use with captopril can increase plasma concentrations of digoxin. Regular monitoring of plasma digoxin concentration is advised.</li><li><strong>Everolimus</strong> — increased risk of angioedema.</li><li><strong>Alpha-blockers, antipsychotics, anxiolytics, beta-blockers, calcium channel blockers, clonidine, co-beneldopa, co-careldopa, diazoxide, hydralazine, hypnotics, levodopa, MAOIs, methyldopa, minoxidil, moxisylyte, moxonidine, nitrates, sodium nitroprusside, tizanidine </strong>— enhanced hypotensive effect.</li><li><strong>Insulin, metformin, and sulfonylureas</strong> — enhanced hypoglycaemic effect.</li><li><strong>Corticosteroids, oestrogens</strong> — hypotensive effect antagonised with concomitant use.</li><li><strong>Lithium</strong> — concomitant use can increase plasma levels of lithium. Regular monitoring of serum lithium concentrations is advised.</li><li><strong>Sacubitril</strong> — manufacturer advises avoiding ACE inhibitors for 36 hours before or after sacubitril.</li><li><strong>Sodium Aurothiomalate</strong> — flushing and hypotension reported.</li><li><strong>Spironolactone</strong> — increased risk of severe hyperkalaemia — use lowest possible dose of both drugs and monitor renal function closely.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">BNF 76, 2018</a>]</p><!-- end field 707657e7-da99-4ed1-8610-aa1400f45ac9 --><!-- end item 60dbbb38-8b81-4c50-a48b-aa1400f45a8f -->","subChapters":[]},{"id":"3b9e65fb-72f7-55aa-be0c-82e4d278461e","slug":"covid-19","fullItemName":"COVID-19","depth":3,"htmlHeader":"<!-- begin field 4b30eddc-67d0-4c54-9aa5-abc200ffdd0e --><h3>COVID-19</h3><!-- end field 4b30eddc-67d0-4c54-9aa5-abc200ffdd0e -->","summary":"","htmlStringContent":"<!-- begin item d1e06cf2-2c9e-4338-a8d5-abc200ffdcc4 --><!-- begin field e1290115-c1c8-4218-be7d-abc200ffdd0e --><ul><li>People who are taking ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin receptor blocker) medications for any indication should not stop taking these drugs during the COVID-19 pandemic, whether they are unaffected by the virus or have contracted the disease.</li><li>The reason for this is that there is no evidence from the limited published literature that taking these medications adversely affects outcomes from COVID-19 or the likelihood of acquiring the infection.</li><li>Stopping the medications, however, is associated with adverse outcomes. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mi-secondary-prevention/references/\">NICE, 2020</a>]</p><!-- end field e1290115-c1c8-4218-be7d-abc200ffdd0e --><!-- end item d1e06cf2-2c9e-4338-a8d5-abc200ffdcc4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}